Grants

awarded

The METAvivor Research Program was established in 2009 with the specific goal of funding stage IV metastatic breast cancer research to one day, end death from metastatic breast cancer (MBC). The following list includes current and past grant recipients along with their progress reports.

Carol Lange, PhD

University of Minnesota

Presented In Memory of Rhonda Rhodes, Co-Founder of Metavivor

Targeting Activated Progesterone Receptors in Metastatic Breast Cancer

Jungwoo Lee, PhD

University of Massachusetts Amherst

Tissue-engineered bone to determine the impact of chemotherapy-induced premature aging in breast tumor metastasis

Adrian Lee, PhD

University of Pittsburgh, UPMC Hillman Cancer Center

Targeting RET for the treatment of breast cancer brain metastasis

FRANSISCA LEONARD, PhD

Houston Methodist Hospital Research Institute

CRISPR-nanoparticle for macrophage reprogramming: New therapeutic strategy for breast cancer liver metastasis

Nancy Lin, MD

Dana-Farber Cancer Institute

Overcoming Treatment Resistance in Breast Cancer Brain Metastases

Laurie Littlepage, PhD

University of Notre Dame

Targeting Endocrine Therapy Resistance in Bone Metastasis

Bolin Liu, PhD

Department of Genetics Stanley S. Scott Cancer Center School of Medicine Louisiana State University Health Sciences Center

Presented in Memory of Cecilia “CeCe” Curry, METAvivor Board Member

IGF-2 in Herceptin refractory HER2-positive breast cancer

Hui-Wen Lo, PhD

McGovern Medical School The University of Texas Health Science Center at Houston

Presented by Midland Park’s Third Annual Color Fun Run in memory of Ashley Rizzuto & Angela Rogers

Targeting Established Brain Metastases of Triple-negative Breast Cancer Using A Novel Combination of Two FDA-Approved BBB-permeable Kinase Inhibitors

Hui-Wen LO, PhD

McGovern Medical School at The University of Texas Health Science Center, Houston

Presented by METAvivor’s community of followers on social media in honor of all of those touched by metastatic breast cancer

Targeting Breast Cancer Brain Metastases by an FDA-Approved Antifungal Drug and its Novel Analog

Paul Lockman, PhD

West Virginia University

Timing of radiotherapy and chemotherapy to improve drug effect in brain metastases of breast cancer

Michael Lukey, PhD

Cornell University

Presented by Minneapolis Metsquerade in honor of Erin Remme

Targeting the unique metabolic profile of brain metastases in breast cancer

David Lum, PhD

Oklahoma Medical Research Foundation

Validation of patient-derived breast tumor grafts as predictors of tumor evolution and drug resistance